CLIA Waived, simple two-step procedure for whole blood.Clearly differentClearview's innovative technology provides highly accurate detection of HIV-1 and HIV-2.
Clearly betterClearview HIV 1/2 STAT-PAK provides answers for immediate and necessary treatment.
About HIVHuman immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) remain leading causes of illness and death in the United States. However, at the end of 2003, of the approximately 1.0--1.2 million persons estimated to be living with HIV in the United States, an estimated one quarter (252,000--312,000 persons) were unaware of their infection and therefore unable to benefit from clinical care to reduce morbidity and mortality. A number of these persons are likely to have transmitted HIV unknowingly. 1 Treatment has improved survival rates dramatically, especially since the introduction of highly active antiretroviral therapy (HAART) in 1995. However, progress in effecting earlier diagnosis has been insufficient. The good news is that the new CDC guidelines have removed much of the barriers to screening and now encourages testing all persons 13-64 years of age in the United States. New HIV Screening GuidelinesIn September 2006, the CDC announced revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. The new guidelines highlight:
This represents a substantial change from earlier recommendations:
Product OverviewThe Clearview HIV 1/2 STAT-PAK is a rapid in vitro qualitative immunoassay for the detection of antibodies to HIV1 and HIV 2 in human whole blood, serum and plasma. With its simple, two-step procedure, Clearview HIV 1/2 STAT-PAK is quick and easy to use, delivering clear, dependable results in just 15 minutes. Plus, Clearview HIV 1/2 STAT-PAK is waived for whole blood and requires a very small sample amount, making it easier to run and manage in a busy laboratory environment. Clearview HIV-1/2 STAT-PAK will help healthcare workers diagnose individual infection, prevent mother-to-child transmission, and monitor HIV prevalence. FAQ’s1. How sensitive is Clearview HIV 1/2 STAT-PAK? 2. How should Clearview HIV 1/2 STAT-PAK be stored? 3. What type of patient sample do I have to use? 4. How critical is the timing? 5. How long are the results stable? 6. The Test Line was fainter than the Control Line, what does this mean? 7. No line has appeared in the Control Window, what does this mean? 8. What is the shelf-life of Clearview HIV 1/2 STAT-PAK? 9. If I add whole blood and forget to add running buffer will the test still run? 10. Would a negative result conclude that a patient does not have HIV?
11. What are the storage conditions for Serum and Plasma samples? 12. What are the storage conditions for whole blood samples? 13. What volume does the sample loop deliver? Reference 1. www.cdc.gov Legal Manufactured by Chembio Diagnostic Systems, Inc., Medford, NY for Inverness Medical
Professional Diagnostics under issued patents U.S. 6,352,862; 6,534,320; 5,622,871; 5,656,503;
|
Specifications
Launch Product Demonstration
Useful Downloads
Product Brochure
Package Insert * It is always the provider's responsibility to establish appropriate coding & charges. |
||
| Product Catalog | Contact Us | Privacy Statement | Terms of Use | Legal | Inverness Medical Innovations | Webmaster | |||